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Abstract
Background: Immunization of rhesus macaques against Gag of SIV resulted in a more rapid appearance of Env
antibodies after infection with SIV or SHIV challenge viruses although the vaccines lacked an Env component. We
therefore explored whether T helper cells specific for internal HIV proteins could provide intrastructural help for
Env-specific B cells and thus increase the Env antibody response.
Results: Mice were immunized by adenoviral vector or DNA vaccines against GagPol and then boosted with virus-
like particles (VLP) containing GagPol and Env. Env-specific antibody levels after the VLP booster immunizations
were significantly higher in GagPol-immunized mice than in mock-vaccinated controls. Adoptive transfer of CD4+ T
cells from GagPol-immunized mice also enhanced the Env antibody response to VLP immunization in the recipient
mice. Depending on the presence of VLPs, co-cultivation of CD4+ T cells from GagPol-primed mice with BCR
transgenic B cells specific for a protein presented on the surface of the VLPs also resulted in the activation of the B
and T cells.
Conclusions: Our study indicates that GagPol-specific T helper cells may provide intrastructural help for Env
antibody responses. This cross-talk between immune responses directed against different components of the
retroviral particle may be relevant for the immunopathogenesis of retroviral infections and allow to improve virus
like particle vaccine approaches against HIV.
Keywords: SIV, HIV VLPs, Gag specific CD4+ T cells, Env antibody response, Intrastructural help
Background
During HIV infection, the immune system encounters
the virus in the form of free virions, infected cells, and
viral proteins (either soluble or as part of cellular debris).
Although the response of the immune system to single
HIV proteins has been studied extensively, how immune
responses to one viral protein affect the response to a
second has been rarely explored. Given the higher-order
structures viral proteins are enclosed in, these interac-
tions may be relevant for immune control and immune
escape. Suggestive evidence for such a cross-talk of im-
mune responses directed against different lentiviral pro-
teins has been obtained in vaccine studies, in which
non-human primates were immunized against Gag of
SIV and subsequently challenged with SIV or SIV-HIV
hybrid viruses. In at least three independent studies the
Env-specific or neutralizing antibody response early after
challenge virus infection seemed to be higher in Gag im-
munized macaques than in the control group [1-3]. In
one of these studies, three of four animals immunized by
an adenoviral vector encoding Gag had raised neutralizing
antibodies at day 40 after SHIV challenge, while none of 4
control animals raised neutralizing antibodies until day 67
after infection [3]. Similarly, Casimiro et al. report weak
neutralization titers in Gag-immunized vaccine groups
already at day 24 after SIVmac239 infection, while detect-
able neutralization titers were observed no earlier than
day 136 post infection in a subset of control animals. In
the third study, macaques with pre-existing anti-Gag
responses developed more rapid kinetics of antibody-
dependent cell-mediated virus inhibition (ADCVI) which
became detectable as early as day 14 after challenge [2].
One explanation by which Gag-specific immunity may
increase Env-specific antibody responses is based on
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cades ago for influenza virus and hepatitis B virus [4-8].
Naïve B-cells specific for external viral proteins may
take-up the entire viral particle and subsequently present
peptides derived from external and internal viral proteins
on their MHC-II molecules. Thus, Gag-specific T helper
cells induced by vaccination could provide cognate help
for Env-specific B cells and thus accelerate the production
of Env-specific antibody responses early after infection. To
test this hypothesis, we re-analysed data from a non-
human primate study, performed immunization and Tcell
transfer experiments in mice, and explored intrastructural
help by in vitro B and Tcell co-culture experiments.
Results
To confirm that immunization against Gag enhances the
Env antibody response in non-human primates after
challenge virus infection we used the comprehensive
data set of the study by Liu et al., [2]. In this study, ma-
caques had been immunized with different serotypes of
adenoviral vectors encoding SIV Gag either as a hom-
ologous or heterologous prime boost regimen inducing a
broad spectrum of Gag-specific T cell responses [2].
Depending on the vaccine regimen, peak viral load levels
after challenge with SIVmac251 were reduced by 0.5 to
1.4 log. Challenge virus infection resulted in rapid anam-
nestic Gag-specific cellular and humoral immune re-
sponses. Surprisingly, ADCVI activity, which was shown
to be dependent on Env-specific antibodies [9], was
already detectable in all vaccinated animals two weeks
after challenge, while in the mock-vaccinated control an-
imals, ADCVI activity was first observed at four weeks
after challenge [2]. The ADCVI activity at two weeks after
infection was significantly higher in Gag-immunized ma-
caques than in mock-vaccinated control animals and there
was an inverse correlation of ADCVI activity and viral
load levels (Figure 1A, B). In line with these findings, the
Env antibody titers also followed more rapid kinetics in
the vaccinated macaques. Already two weeks after chal-
lenge seven of the 16 vaccinated macaques showed an in-
crease in Env specific antibody levels while none of the
control animals did. This difference reached statistical sig-
nificance four weeks after challenge (Figure 1C). However,
neither the viral load nor the area under the viral load
curve correlated with week 2 or week 4 Env antibody ti-
ters (Figure 1D and data not shown).
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Figure 1 Antibody responses to Env after SIV infection in macaques immunized against Gag. ADCVI activity (A) and antibody titers to Env
(C) at 2 and 4 weeks after SIVmac251 infection in control monkeys (sham, n=6) and monkeys vaccinated against Gag by different prime boost
regimens with vectors based on adenovirus types 5, 26, or 35 (Ad-Gag, n= 16). Mean titers with SEM are shown. B) Correlation analysis of ADCVI
activity and viral load at week 2. D) Correlation analysis of Env antibody titers at week 4 with the viral load during the first 4 weeks after
challenge. AUC: area under the viral load curve. Groups were compared by the Mann–Whitney test (A, C) and data were evaluated by the
Spearman rank correlation test (B, D). All data are derived from [2].
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Gag or Pol proteins present in the virus particles could
directly provide help for Env-specific antibody responses
by the intrastructural help mechanism. Mice were
primed with an adenoviral vector encoding SIV-Gag and
Pol (Ad-Sgp) or an adenoviral vector encoding GFP (Ad-
GFP). Six weeks later both groups received virus-like
particles (VLP) containing SIV-Gag, Pol, and Env proteins.
After the VLP immunization, the Env-specific IgG1 and
I g G 2 aa n t i b o d yl e v e l sw e r e1 0t o5 0 - f o l dh i g h e ri nm i c e
primed with the Ad-Sgp vector than in mice which received
Ad-GFP (Figure 2). In Ad-Sgp primed mice, the SIV Env-
specific antibody response after the VLP immunization was
also 10 to 50-fold higher than after booster immuniza-
tions with exosomes containing the same amounts of
SIV Env as the VLP preparation but lacking GagPol
(Figure 2). Since the SIV Env specific antibody response
after VLP immunization of mice that had not been
primed against SIV GagPol was similar to response
after exosome immunization, the enhancement of the
Env-specific antibody response in GagPol immunized
mice is dependent on the presence of GagPol in the
VLPs.
To address the question, whether GagPol-specific T-
cells induced by prior immunization were responsible
for the enhanced antibody response to Env, we performed
adoptive transfer experiments. Whole splenocytes, CD4+
T cells or CD8+ T cells of donor mice were isolated six
weeks after immunization with either Ad-Sgp or Ad-GFP
and transferred into syngeneic recipient mice, which then
were immunized with VLPs at day 5 and 55 after transfer.
Higher Env-specific IgG1 and IgG2a levels were observed
after transfer of either splenocytes or CD4+ T cells from
Ad-Sgp immunized donor mice (Figure 3), fully consistent
with intrastructural help by Gag and/or Pol-specific CD4+
T cells. Transfer of splenocytes or CD4+ T cells from Ad-
GFP immunized mice and CD8+ Tcells from both groups
of immunized mice did not increase the Env-specific
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Figure 2 IgG1 and IgG2a antibody levels to SIVgp130 at 1, 3
and 6 weeks after SIV VLP boost in mice primed 6 weeks
earlier with adenoviral vectors encoding SIV GagPol or GFP.
Single and mean values of 3 to 9 animals per group from two
independent experiments are given. *P< 0.05, **P<0.01, Mann
Whitney test.
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Figure 3 IgG1 and IgG2a antibody levels to SIVgp130 after cell
transfer and subsequent VLP immunization. Donor mice (D)
were immunized with adenoviral vectors encoding SIV GagPol or
GFP. Six weeks later splenocytes (S), CD8-depleted splenocytes (4+),
and CD4-depleted splenocytes (8+) were transferred into syngeneic
recipient mice. The recipient mice and remaining donor mice were
immunized with SIV VLPs 5 and 55 days after cell transfer. Mean and
standard errors of IgG1 and IgG2a antibody levels to SIVgp130 of
four animals per group are shown at the indicated days after the
first VLP immunization. Statistically significant differences between
the Ad-GFP and the Ad-Sgp group are marked by asterisks (p< 0.05,
Mann Whitney test).
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ent mice.
Although the exosome experiments described above
argue against it, one explanation for the enhanced Env-
specific antibody responses could be a cross reaction of
SIV Gag or Pol-specific T-helper cells with SIV Env-
derived peptides presented on MHC-II molecules. There-
fore, Ad-Sgp primed mice were also boosted with VLPs
containing SIV-Gag, Pol and HIV-Env. Since HIV and SIV
Env only have a 36% amino acid identity a random cross
reaction of SIV Gag or Pol-specific T helper cells with a
second Env protein seems highly unlikely. Again, HIV-Env
specific IgG1 and IgG2a antibody levels were significantly
higher in GagPol immunized mice than in Ad-GFP
control mice (Figure 4A) further arguing against a cross-
reaction on the T helper cell level.
To further extend this observation to HIV particles,
mice were also primed against HIV GagPol by a single
intramuscular DNA electroporation and boosted five and
eight weeks later with VLPs containing HIV Gag, Pol, and
Env proteins. The DNA electroporation induced polyfunc-
tional CD4+ T cells specific for immunodominant Gag
peptides (Figure 4B). Concomitantly, Env-specific IgG2a
levels increased after the VLP immunizations more rapidly
and to higher levels in the GagPol-immunized mice than
in the control mice (Figure 4D), confirming the observa-
tion that GagPol-specific immune responses may increase
the antibody response to Env after VLP immunization. A
trend to higher Env-specific IgG1 antibody levels was also
observed, but this increase did not reach statistical signifi-
cance and the magnitude of the increase was lower than
for IgG2a (Figure 4C).
To corroborate our hypothesis, that GagPol specific
CD4+ T cells provide help to B cells specific for surface
protein of viral particles we further studied the inter-
action of B cells and T cells in vitro. Therefore, we took
advantage of B cell receptor transgenic mice specific for
the model antigen hen egg lysozyme (HEL). The Env
protein of HIV VLPs was replaced with HEL by fusing it
to the transmembrane and intracytoplasmic domain of
the G-protein of vesicular stomatitis virus [10]. To verify
that the uptake of VLPs by B cells is BCR dependent we
included VLPs lacking HEL in our experiments.
GagPol-specific T cells were derived from mice
immunized against HIV GagPol by adenoviral vector
immunization. To avoid potential unspecific stimulation
due to the inflammatory effect of adenoviral vector par-
ticles, T cells were recovered three to four months after
the last adenoviral vector immunization. Co-culture of
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Figure 4 Intrastructural help for HIV Env. A) Mice were immunized with Ad-Sgp and boosted with SIV VLPs containing HIV Env 6 and 9 weeks
later. Mean and SEM of Env-specific IgG1 and IgG2a antibody levels 2 weeks after the last VLP immunization from 6 animals per group are given.
B-D) Mice were immunized with an HIV GagPol expression plasmid (Hgp) or empty pcDNA as control by intramuscular DNA electroporation. Gag
specific CD4+ T-cell responses were analyzed 14 days after priming by intracellular cytokine staining of in vitro restimulated splenocytes. Shown
are the percentages of cytokine producing cells among the total CD4+ T-cell population (B). HIV gp120 specific antibody levels of the subtypes
IgG1 (C) and IgG2a (D) in the sera of immunized mice were determined by ELISA four weeks after DNA prime (day 28), one and two weeks after
the first (day 42 and 49) and one week after the second VLP boost (day 64). Columns represent the mean values with SEM of 5–6 animals.
*P< 0.05, **P<0.005, Mann Whitney U test.
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controls. In the presence of HEL-VLPs and DCs, co-
culture of the HEL B cells with the control CD4+ Tcells
resulted in low level activation of HEL B cells as indicated
by upregulation of CD69 (Figure 5A). This activation
increased substantially when CD4+ Tcells from spleens of
GagPol-immunized mice were used and was clearly
dependent on the presence of HEL-VLPs (Figure 5A). Co-
culture of HEL B cells, with CD4+ T cells from spleens of
GagPol-immunized mice and DCs in the presence of
VLPs lacking HEL did not increase CD69 expression. Pre-
incubation of DCs with HEL-VLPs prior to co-culture
with HEL B cells and GagPol-specific Tcells did not result
in the activation of the B cells either indicating a require-
ment for direct interaction of HEL-VLPs with the HEL B
cells (data not shown). Since the CD4+ T cells were de-
rived from the GagPol immunized mice more than 12
weeks after the last adenoviral vector immunization
antigen unspecific activation of the HEL B cells by the
CD4+ T cells from the adenoviral vector immunized mice
was considered to be highly unlikely.
To check if our in vitro results directly translate into the
animal model, we adoptively transferred CFSE-labelled
HEL B cells in GagPol immunized or non-immunized
mice. The immunized recipient mice received the HEL
B cells 13 weeks after the last adenoviral vector
immunization to avoid an influence of the inflammatory
response induced by adenoviral vector particles. An ex-
tensive proliferation of the transferred HEL B cells was
observed only in GagPol immunized mice receiving
HEL VLPs (Figure 5B), which is fully consistent with a
stimulatory effect of GagPol-specific T helper cells on B
cells specific for the surface protein of VLPs.
In addition to the stimulation of B cells, we further an-
alyzed the activation of CD4+ T cells in our in vitro co-
cultures. The interaction of CD4+ T cells from GagPol
immunized mice, HEL-specific B cells, and DCs in the
presence of HEL-VLPs resulted in the upregulation of
CD154 (CD40L), indicating that the T cells became com-
petent to provide help for cognate B cells (Figure 6A).
CD4+ T cells from non-immunized mice were not
activated by co-incubation with DCs, HEL-B cells, and
HEL-VLPs. Co-culture of CD4+ T cells from GagPol-
immunized mice with DCs, HEL-B cells and VLPs lack-
ing HEL did not result in CD4+ T cell activation either.
This indicates that B cells can indeed take up HIV-VLPs
by BCRs specific for proteins from the surface of the
VLPs and present internal GagPol-derived peptides to
GagPol-specific T cells.
To further explore the outcome of the interaction
between DCs, B cells, and CD4+ T cells in the presence
of VLPs containing matched B and T cell epitopes from
different proteins of the VLP, the differentiation of the
CD4+ T cells into follicular T helper cells (fTH) was in-
vestigated by determining co-expression of CXCR5 and
BCL-6 (Figure 6B) as an established indicator of the fTH
phenotype. Co-culture of B cells from SW-HEL mice with
T cells from either naïve or Ad-Hgp immunized mice did
not induce fTH cells (Contr. column in Figure 6B), indi-
cating that CD4+ T cells from Ad-Hgp mice do not lead
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Figure 5 Activation and proliferation of HEL specific B cells exposed to HEL-VLPs. (A) Naïve B-cells from SW-HEL mice were co-cultured for
one day with splenic DCs and CD4+ T-cells from either non-immunized (naive) or GagPol immunized (Ad-Hgp) mice in the presence of HEL-VLPs
or control VLPs lacking HEL. Cells were stained with Alexa488-conjugated HEL and antibodies to B220 and anti-CD69. The CD69 expression
pattern of HEL+B220+ cells is shown. The experiment was performed three times with similar results, data of one representative experiment are
shown. (B) Naïve B-cells from SW-HEL mice were labelled with CFSE and adoptively transferred into non-immunized or GagPol-immunized mice.
Two hours later, half of the acceptor mice were injected i.v. with HEL-VLPs. Three days later, spleen and LN cells were stained with Alexa647-
conjugated HEL-and anti-B220 antibodies. The CFSE fluorescence intensity of HEL+B220+ cells is shown. Two independent experiments with
three to four mice were performed. Representative data are shown.
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HEL to these co-cultures we observed a trend to a higher
percentage of fTH cells in the presence of CD4+ T cells
from GagPol primed mice (VLP column in Figure 6B). As
a source of B-cells SW-HEL BCR-transgenic mice on a
RAG +/+ background were used. Therefore, only up to
40% of the B-cells from these SW-HEL mice carry the
HEL-specific BCR, while the rest of the B cell population
has undergone VH gene replacement leading to a broad
BCR repertoire. Therefore, these non-HEL B-cells may
also take-up VLPs in a BCR-dependent or independent
manner and present HIV GagPol-derived peptides on
MHC-II molecules explaining the observed trend to a
higher percentage of fTH cells in the presence of CD4+ T
cells from GagPol-primed mice. Adding exosomes con-
taining HEL, but lacking GagPol, also enhanced fTH
induction. However, this was clearly independent of the
Ad-Hgp immunization (HEL-Exo column in Figure 6B)
and may be explained by more efficient uptake of the HEL
exosomes by the HEL B cells and subsequent presentation
of exosome-derived peptides from human proteins to the
T helper cells derived from GagPol-primed and naive con-
trol mice. In the presence of naïve T cells, addition of
HEL-VLPs resulted in a similar percentage of fTH as ob-
served for HEL exosomes. Importantly, co-culture of
HEL-VLPs with HEL B cells and CD4+ T cells from
GagPol-primed mice induced a significantly higher per-
centage of fTH cells than the corresponding co-culture
with T helper cells from naïve mice. In addition, the per-
centage of fTH cells in the presence of GagPol primed T
cells was significantly higher after stimulation with HEL-
VLPs than HEL exosomes demonstrating the specificity
for GagPol. The follicular T helper phenotype was further
confirmed by GL7 positivity of nearly all of the CD4+
BCL-6+CXCR-5+ (data not shown). Omitting HEL B
cells from the co-culture blocked differentiation of the T
helper cells into fTH completely (data not shown). In the
absence of DCs, differentiation into fTH by HEL-VLP ex-
posed B cells was detectable, but less efficient. Thus, most
efficient induction of fTH cells required triggering of cog-
nate T- and B-cells by their respective antigens.
Discussion
Our mouse experiments clearly demonstrate that GagPol-
specific CD4+ T cells can increase the Env antibody re-
sponse after exposure to virus-like particles of SIV and
HIV. Mechanistically, our results are fully consistent with
the intrastructural help hypothesis, by which B-cells spe-
cific for external viral proteins take-up the entire viral
particle and subsequently present peptides derived from
external and internal viral proteins on their MHC-II mole-
cules. Thus T helper cells specific for the peptides from
the internal viral protein may provide cognate help for B
cells encoding antibodies against the external protein.
Whether the intrastructural help observed in the present
study using VLP immunization is similar to that occurring
during viral infection is unclear. This may largely depend
on the relative contributions of virions, cell-associated
viral antigens, or soluble viral proteins on the antibody re-
sponse to the viral surface protein. Priming of mice with
influenza virus cores or purified M protein clearly en-
hanced the antibody response to HA after influenza virus
Naive
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Ad-Hgp + VLP
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Figure 6 Activation and differentiation of CD4+ T cells by HEL-specific B-cells exposed to HEL-VLPs. CD4+ T-cells from non-immunized
(naive) or GagPol immunized (Ad-Hgp) mice were co-cultured with naïve B-cells from SW-HEL mice and splenic DCs in the presence of HEL-VLPs
or control VLPs lacking HEL. (A) After one day, cells were stained for CD4 and the CD-154 activation marker. The experiment was performed three
times with similar results, data of one representative experiment are shown. (B) After 6 days of incubation, cells were stained for CD4, intracellular
BCL-6, and CXCR-5. Follicular-helper cells were defined by co-expression of BCL-6 and CXCR-5. Numbers in upper right corners indicate mean
percentage ± standard deviation of follicular-helper cells among total CD4+ T cells from three independent experiments. Each of the three
experiments was performed in duplicates and the mean of the duplicates was used for statistical analysis of the mean of the three experiments.
P values of unpaired t-tests for the indicated group comparisons are shown.
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specific T helper cell clones also enhanced the HA-
antibody response to influenza virus infection in nude
mice to a similar extent [5]. In contrast, a vaccinia virus
infection model revealed that CD4+ T cells specific for an
epitope of one protein of the vaccinia virus particle did
not enhance the antibody response to another protein of
the virion [11]. In addition, there was an extensive overlap
of vaccinia virus proteins recognized by T-helper cells
and targeted by antibodies indicating that individual
proteins are the unit of Tcell – B cell interaction at least
for a large virus [11].
Whether intrastructural help leads to a modulation of
the antiviral immune response during natural HIV/SIV
infection is unknown and difficult to explore. Faster kin-
etics of the antibody titers to Env and the ADCVI activ-
ity observed in non-human primates vaccinated against
Gag after challenge virus infection provide some evi-
dence. However, secondary effects such as differences in
the preservation of immune competence need to be ex-
cluded. Although we did not observe an inverse correl-
ation between viral load and Env antibody titers, further
analyses on the correlation of Env antibody levels and
Gag-specific cellular immune responses early after chal-
lenge virus infection are needed to further strengthen
the hypothesis.
In contrast to the Env antibody titers as determined
by ELISA, the ADCVI activity correlated inversely with
v i r a ll o a ds u g g e s t i n gt h a tA D C V Im a yc o n t r i b u t et o
control of virus replication. Since the Env antibody ti-
ters and the ADCVI activity do not correlate (data not
shown), the two parameters of the Env antibody re-
sponse probably reflect different functionalities of Env
antibodies. This suggests that intrastructural help can
not only be exploited to increase the Env antibody re-
sponses, but also to modulate it by for example prefer-
ential induction of antibody isotypes conferring ADCVI
activity. Preferential stimulation of HIV Env-specific
IgG2a antibody responses in mice immunized against
HIV GagPol by DNA electroporation provides some ex-
perimental support for such an approach.
Our observation that GagPol-specific T helper cells
may provide help for Env antibody responses has impli-
cations for the conclusions that can be drawn from T
cell based vaccine studies on effector mechanisms medi-
ating control of virus replication. Since Env is the only
viral protein of the intact virion accessible to antibodies,
durable control of virus replication after immunization
with vaccines lacking an Env component has been taken
as evidence for the potency of cytotoxic T cells. Due to
intrastructural help, the antibody response to the Env of
the actual challenge virus may be raised more rapidly and
could thus contribute to control of virus replication by
neutralization or non-neutralizing antibody-dependent
effector mechanisms, like ADCVI. At the same time,
intrastructural help by GagPol-specific T helper cells
may be an effective way to improve the efficacy of vac-
cines originally designed to raise protective Env anti-
body responses. In the absence of sterilizing immunity,
break-through virus infections may be controlled more
efficiently by a more rapid ADCVI activity facilitated by
GagPol-specific T helper cells.
The VLPs used in the present study are not only tools
to dissect the interaction of viruses with the host im-
mune system, but are also promising vaccine candidates.
Presentation of the Env protein in its native membrane-
embedded conformation and increased immunogenicity
in comparison to soluble proteins are favourable charac-
teristics of VLP vaccines. Thus, it may also be possible
to exploit the intrastructural help effect observed in the
present study to enhance and modulate the immune re-
sponses raised by VLP vaccine candidates using GagPol-
specific T helper cells.
Conclusions
GagPol-specific T helper cells can clearly increase the
Env antibody response to VLP immunization and may
also explain the higher Env antibody responses during
breakthrough infections in non-human primates only
immunized against Gag. It remains to be determined
how this cross-talk between immune responses directed
against different components of the retroviral particle af-
fects the immunopathogenesis of retroviral infections.
Intrastructural help is an attractive strategy to increase
and modulate the immunogenicity of VLP vaccines.
Methods
Mice
Mice were housed at the animal facility of the faculty of
medicine, Ruhr University Bochum, Germany in singly-
ventilated cages in accordance with the national law and
institutional guidelines and were handled according to
the Federation of European Laboratory Animal Science
Association. Six to eight weeks-old C57BL/6J mice (BL6),
BALB/c and SW-HEL mice were used in this study. The
BCR-transgenic SW-HEL mice were kindly provided by
Dr. A. Freitas, The Lymphocyte Population Biology Unit,
Pasteur Institute, France.
DNA immunization
The codon-optimized HIV GagPol expression plasmid
Hgp (designated Hgpsyn in [12]) and the empty vector
pcDNA3.1 (Invitrogen, Carlsbad, CA, USA) were prepared
using the NucleoBond® Xtra Maxi EF Kit (Macherey-Nagel,
Düren, Germany) and diluted in sterile PBS. The mice
were anaesthetized by intraperitoneal injection of 50 mg/
kg body weight Ketamin (CP-Pharma, Burgdorf, Germany)
and 10 mg/kg body weight Xylazin (Bayer, Leverkusen,
Nabi et al. Retrovirology 2013, 10:117 Page 7 of 10
http://www.retrovirology.com/content/10/1/117Germany). The hind legs were shaved prior to insertion of
the TriGrid™ electrode array (Ichor Medical Inc., San
Diego, USA) bearing the centred injection needle. Fifty μl
containing 10 μgH g p + 1 0μgp c D N A 3 . 1o r2 0μg
pcDNA3.1 alone were injected intramuscularly in each
hind leg followed by the electric pulse.
Adenoviral vector immunization
The recombinant adenoviruses Ad-Hgpsyn expressing
codon-optimized HIV-GagPol and Ad-Sgpsyn expressing
codon-optimized SIV-GagPol have been described previ-
ously [13,14] and are designated Ad-Hgp and Ad-Sgp in
this manuscript respectively. Ad-GFP expressing GFP
has also been described previously [14]. The adenoviral
vectors were purified from T-Rex-293 cells (Invitrogen,
Karlsruhe, Germany) by CsCl density gradient centrifu-
gation as reported previously [13]. The concentration of
the adenoviral vector particles in the vector stocks was
determined by measuring the optical density at 260 nm.
For the adenoviral vector prime VLP booster immu-
nization experiments, 6–8 weeks old BALB/c mice were
immunized subcutaneously with 1×10
9 particles of Ad-Sgp,
Ad-Hgp or Ad-GFP. For in vitro experiments, BL6 mice
were immunized twice with a two month interval with 10
10
particles of Ad-Hgp. Antibody responses to Gag confirmed
the immunogenicity of the vector immunization.
VLP production and immunization
For efficient incorporation of SIVgp140 and HIVgp140, into
VLPs, the respective coding regions were fused in frame to
the intracytoplasmic domain of VSV-G. The HEL incorpor-
ation into VLPs was facilitated by the HEL coding region
fused in frame to the transmembrane and intracytoplasmic
domain of VSV-G. The expression plasmid SIVgp140-
GTM contains a codon-optimized sequence coding for
amino acid 23 to 682 of Env of SIVmac239 (numbering
according to Genbank entry M33262.1 fused to amino
acid 97 to 122 of VSV-G (Genbank entry CAA24524.1).
pConBgp140GCD contains a codon-optimized clade B
consensus sequence encoding amino acid 1 to 703
(Genbank entry ABG67916.1) fused to the intracyto-
plasmic domain of VSV-G (Amino acid 97 to 122, Gen-
bank Entry CAA24524.1). pHEL-GCD encodes amino
acid 1 to 147 (numbering according to Genbank entry
ACL81762.1) fused to the transmembrane and intracy-
toplasmic domain of VSV-G (Amino acid 52 to 122 ac-
cording to Genbank entry CAA24524.1). SIV virus like
particles were produced by transient co-transfection of
HEK293Tcells with Sgpsyn [12] and SIVgp130-GTM by
the calcium phosphate coprecipitation method.
SHIV, HIV, and HEL VLPs were prepared by transient
transfection of HEK 293T cells with the polyethyleni-
mine method [15]. In brief, one day prior to transfection
293T cells were seeded in 175 cm
2 cell culture flasks
(Greiner Bio One, Frickenhausen, Germany) to reach 60 -
80% confluency on the next day. For SHIV VLPs 35 μg
Sgpsyn and 35 μg pConBgp140GCD, for HIV VLPs 35 μg
Hgp and 35 μg pConBgp140GCD, and for HEL VLPs
35 μg of Hgp with 35 μg of pHEL-GCD were mixed in
5 ml serum free DMEM (Invitrogen, Carlsbad, CA, USA)
per 175 cm
2 flask. Subsequently, 105 μlo f1μg/μlp o l y -
ethylenimine (1:1.5 DNA to polyethylenimine) were added
and the solution was thoroughly mixed. Following 15 min
incubation at RT the transfection mixture was added to
the cells. After 6 h the medium was exchanged with a 1:1
mixture of serum free DMEM and AIM-V (Invitrogen,
Carlsbad, CA, USA). To harvest the VLPs the supernatant
was collected 48 h after transfection and centrifuged for
10 min at 940× g to remove dead cells and cellular debris.
Following filtration through a 0.45 μm filter the VLPs were
purified by ultracentrifugation through a 20% sucrose
cushion for 2.5 h at 90,000× g at 4°C. After discarding the
supernatant the VLPs were resuspended in PBS and stored
at −80°C.
The VLPs were characterized by Western Blot using
serum from an SIV-infected macaque (serum 1604,
German Primate Centre) or HIV-IG (BP1035 - Acris
antibodies GmbH). To determine the amount of Env
and HEL in the VLP preparations, high binding microti-
ter plates (Greiner Bio One, Frickenhausen, Germany)
were coated with the purified VLPs or serial dilutions of
known amounts of SIVgp130 (EVA670, NIBSC), HIVgp120
(HIV-1 IIIB, NIH Reference and Reagent Program) or HEL
(Sigma Aldrich). The amounts of SIVgp130, HIVgp120, or
HEL from the VLP preparations bound to the microtiter
plate were then determined using the monoclonal KK45
SIV gp130 antibody (NIH AIDS Reference and Reagent
Program), the monoclonal gp120 antibody 2G12 (Poly-
mun), a rabbit anti-HEL serum (Fitzgerald Industries), and
matched HRP-conjugated secondary antibody reagents.
Exosomes containing SIV Env or HEL were prepared
and characterized as described for SIV VLPs and HEL
VLPs, respectively, by omitting the GagPol expression
plasmids from the transfection reaction.
For the mouse immunization studies the SIV VLPs were
diluted in sterile PBS to a final concentration of 3 μg/ml
gp130 and the HIV VLPs to 4 μg/ml gp120. Mice were
immunized by subcutaneous injection of 100 μld i s t r i b -
uted into both hind foot pads.
To monitor humoral immune responses mice were
bled by puncture of the retro-orbital sinus with a hepa-
rinized micro-hematocrit capillary. Sera were obtained
by centrifugation for 5 min at 2600× g in a table top
centrifuge and stored at −20°C until use.
Determination of antibody levels
SIV and HIV Env-specific humoral immune responses
were analyzed by a gp130 and gp120 specific ELISA
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cells with a C-terminal His-Tag and purified using the Pro-
Pur Midi MC kit (Nunc, Denmark) according to the man-
ufacturer’s instructions. The protein preparations were
90–95% pure as judged by Coomassie staining. Briefly,
white 96-well highbinding microtiter plates (Greiner Bio
One, Frickenhausen, Germany) were coated with 200 ng
of SIVmac239 gp130 or 100 ng of HIV-1 consensus clade
B gp120 in 0.1 M bicarbonate buffer pH 9.6 over night at
4°C. After washing with PBS containing 0.05% Tween-20
(PBS-T) wells were blocked with 5% skimmed milk
powder in PBS-T (blocking buffer) for one hour at room
temperature (RT). Following another washing step sera di-
luted in blocking buffer were added to wells for one hour
at RT. After washing the wells were incubated with HRP-
conjugated anti-mouse IgG1 or IgG2a (BD Biosciences,
Heidelberg, Germany) diluted 1:1000 in blocking buffer
for 1 h at RT. Subsequent to extensive washing bound
antibodies were detected with chemoluminescence
substrate (prepared as previously described) in a micro-
plate luminometer with Simplicity software (ORION-96,
Berthold, Bad Wildbad, Germany) and expressed as
log10 transformed relative light unit (RLU) values.
Determination of cellular immune responses
To determine the HIV Gag specific CD4+ T-cell responses,
spleens were harvested 14 d after DNA priming and single
cell suspension of splenocytes were prepared. After red
blood cell lysis with ACK buffer, 1 × 10
6 cells/well were
plated in 96-well round-bottom plates (Nunc, Denmark).
The cells were stimulated with 5 μg/ml of the HIV Gag-
specific peptides (PVGEIYKRWIILGLN and SPEVIPMF-
SALSEGA) and 2 μg/ml anti-mouse CD3 antibody (BD
Biosciences, Heidelberg, Germany) in the presence of 2
μM Monensin for 6 h at 37°C in a humidified 5% CO2 at-
mosphere. Prior to fixation with 2% paraformaldehyde cells
were stained with anti mouse CD4 PerCP-eFluor® 710 and
Fixable Viability Dye eFluor® 780 (eBioscience, San Diego,
CA, USA). After permeabilization with 0.5% saponin in
PBS/BSA/azide buffer intracellular cytokines were detected
with anti-mouse TNFα Alexa Fluor® 488, anti-mouse IFNγ
PE and anti-mouse IL-2 APC (BD Bioscience, Heidelberg,
Germany). Following extensive washing cells were mea-
sured on a FACS Canto II (BD Bioscience, Heidelberg,
Germany) and analyzed using FlowJo software (Tree Star,
Inc., Ashland, OR, USA).
In vitro co-culture experiments
Naïve untouched CD5
- B2 cells were isolated from sin-
gle cell suspension of splenocytes and lymph node cells
of SW-HEL mice with the B-Cell Isolation Kit (Miltenyi
Biotec GmbH, Germany) according to the manufac-
turer’s instruction. Untouched CD4
+ T-cells were iso-
lated from single cell suspension of splenocytes and LN
cells of naïve and Ad-Hgpsyn immunized BL6 mice with
the T-Cell Isolation Kit (Miltenyi Biotec GmbH). CD4+
Tcells were isolated from immunized mice three to four
months after the last adenoviral vector immunization.
DC were enriched by positive selection form spleen cell
suspensions of BL6 mice with anti-CD11c magnetic
beads (Miltenyi Biotec GmbH, Germany). The resulting
cells were routinely >98% pure. Cells were plated in U-
bottom 96-well plates at a density of 1-3×10
5 CD4-T
cells/well, the B-cells were added in a ratio of 2:1 (B:T)
and DC in a ratio 1:5 (DC:T) and incubated for one or
six days in the presence of HEL- or control VLPs in a
final concentration of 100 ng of HIV-Gag per well. For
indirect B-cell activation experiments, DC were plated
in flat-bottom 96-well plates at the density of 1 × 10
5
cells/well and incubated with both HEL- and control
VLP for 2 h at 37°C. After intensive washing with pre-
warmed medium the cells were transferred into U-bottom
96-well plate and co-cultivated with B- and T-cells as de-
scribed above.
Adoptive transfer
Splenocytes were isolated from immunized BL6 mice and
pooled according to groups. CD4+ and CD8+ T-cells for
adoptive transfer were purified manually from splenocyte
preparations through magnetic columns using the mouse
CD4+ and CD8+ T-cell isolation kits (Miltenyi Biotec,
Germany; Cat.Number 130-090-860 and 130-090-859)
according to the manufacturer’sm a n u a l .T h ep u r i t yo f
isolated CD4+ or CD8+ T-cells was confirmed by flow cy-
tometry. Splenocytes and purified T cells were adoptively
transferred to recipient mice by intravenous tail vein injec-
tion in a total volume of 300 μl. Each recipient mouse re-
ceived the amounts of splenocytes, CD4+ Tcells, or CD8+
T cells recovered from one donor mouse. For the B cell
transfer, 5×10
6 B cells purified as described for the in vitro
co-culture experiments from SW-HEL mice were injected
into the tail vein of the recipient BL6 mice.
Statistical analyses
Two-sided Spearman rank correlation, two-tailed Mann–
Whitney tests, and two-sided unpaired t tests were
performed using the GraphPad Prism software. P values
of <0.05 were considered significant.
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